Biomarker Research and Development for Coronavirus Disease 2019 (COVID-19): European Medical Research Infrastructures Call for Global Coordination

Show full item record



Permalink

http://hdl.handle.net/10138/333419

Citation

Oldoni , E , van Gool , A , Garcia Bermejo , L M , Scherer , A , Mayrhofer , M T , Florindi , F , Demotes , J , Kubiak , C , Fauvel , A-C , Bietrix , F , Ussi , A & Andreu , A L 2020 , ' Biomarker Research and Development for Coronavirus Disease 2019 (COVID-19): European Medical Research Infrastructures Call for Global Coordination ' , Clinical Infectious Diseases , vol. 72 , no. 10 , pp. 1838-1842 . https://doi.org/10.1093/cid/ciaa1250

Title: Biomarker Research and Development for Coronavirus Disease 2019 (COVID-19): European Medical Research Infrastructures Call for Global Coordination
Author: Oldoni, Emanuela; van Gool, Alain; Garcia Bermejo, Laura Maria; Scherer, Andreas; Mayrhofer, Michaela Th.; Florindi, Francesco; Demotes, Jacques; Kubiak, Christine; Fauvel, Anne-Charlotte; Bietrix, Florence; Ussi, Anton; Andreu, Antoni L.
Contributor: University of Helsinki, Institute for Molecular Medicine Finland
Date: 2020-05
Language: eng
Number of pages: 5
Belongs to series: Clinical Infectious Diseases
ISSN: 1058-4838
URI: http://hdl.handle.net/10138/333419
Abstract: An effective response to the coronavirus disease 2019 (COVID-19) pandemic requires a better understanding of the biology of the infection and the identification of validated biomarker profiles that would increase the availability, accuracy, and speed of COVID-19 testing. Here, we describe the strategic objectives and action lines of the European Alliance of Medical Research Infrastructures (AMRI), established to improve the research process and tackle challenges related to diagnostic tests and biomarker development. Recommendations include: the creation of a European taskforce for validation of novel diagnostic products, the definition and promotion of criteria for COVID-19 samples biobanking, the identification and validation of biomarkers as clinical endpoints for clinical trials, and the definition of immune biomarker signatures at different stages of the disease. An effective management of the COVID-19 pandemic is possible only if there is a high level of knowledge and coordination between the public and private sectors within a robust quality framework.
Subject: 11832 Microbiology and virology
3121 General medicine, internal medicine and other clinical medicine
Rights:


Files in this item

Total number of downloads: Loading...

Files Size Format View
Oldoni_Biomarke ... opment_for_Coronavirus.pdf 166.1Kb PDF View/Open

This item appears in the following Collection(s)

Show full item record